Second generation cryoballoon ablation for persistent atrial fibrillation: an updated meta-analysis.

Area of Science:

• Cardiology
• Electrophysiology
• Medical Devices

Background:

• Catheter ablation, specifically pulmonary vein isolation (PVI), is a standard treatment for symptomatic atrial fibrillation (AF).
• Second-generation cryoballoon (2G-CB) technology has demonstrated efficacy in paroxysmal AF and shows promise for persistent AF (perAF).

Purpose of the Study:

• To analyze the safety and mid-term (≥12 months) efficacy of PVI using 2G-CB in patients with perAF.
• To summarize existing data on 2G-CB ablation for perAF.

Main Methods:

• A systematic literature search was conducted across major databases (PubMed, Web of Science, Cochrane Library, clinicaltrials.gov) in December 2016.
• Included studies reported clinical success rates at ≥12 months follow-up, defined as freedom from atrial arrhythmia >30 seconds after a 3-month blanking period.
• Random-effects modeling was used to analyze data on acute success, mid-term efficacy, and complication rates.

Main Results:

• Analysis of 11 studies involving 917 patients showed 68.9% freedom from recurrence at a mean follow-up of 16.7 months.
• The overall acute success rate was 99.7%, with major complications occurring in 5.5% of patients.
• Vascular access complications (3.3%) and phrenic nerve palsy/injury (2.09%) were the most frequent complications; no deaths, strokes, or myocardial infarctions were reported.

Conclusions:

• Second-generation cryoballoon ablation appears to be a safe and effective treatment option for persistent atrial fibrillation in the mid-term.
• The procedure demonstrates a high acute success rate and acceptable complication profile for perAF patients.